ong-term study of HP-3000 in patients with Parkinson's disease
Phase 3
- Conditions
- Parkinson's disease
- Registration Number
- JPRN-jRCT2080222696
- Lead Sponsor
- Hisamitsu Pharmaceutical Co.,Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients diagnosed with Parkinson's disease in stages 1 to 4 on the modified Hoehn & Yahr scale.
Exclusion Criteria
- Patients with history of hypersensitivity to ropinirole.
- Patients with severe hepatic dysfunction.
- Patients who have cutaneous abnormality at planned application site that can be worsen by application with investigational product.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety, and efficacy.
- Secondary Outcome Measures
Name Time Method